Evolus, Inc. (EOLS) - Due Diligence

hourglass

Loading…

Preparing the latest DD data, styles and content.

66OpportunityDD: May 30, 2026Analyst: 67

paidPrice at analysis date

USD 6.18 (30/05/2026)

domainMkt cap

pie_chartShares

candlestick_chart52W

$5.70-$15.90

trending_downShort interest

10.43%

MEDIUMNASDAQHealth Care325 employeesFounded 2012

Verdict: SPECULATIVE-Attractive (asymmetric inflection)

Aesthetic medicine pure-play emerging from a multi-year cash-burn phase: Jeuveau holds 14% U.S. neurotoxin share, Evolysse HA filler franchise just hit second print, Adj EBITDA turned positive in Q4 25 and Q1 26 with FY26 guide of $327–337M revenue and low-to-mid single-digit EBITDA margin. Stock down 42% from 52w high ($10.62) on Q1 revenue micro-miss; valuation at 1.6x EV/Sales fw vs aesthetic-medical peers at 2–4x. Asymmetry case rests on Jeuveau franchise resilience as floor and Evolysse ramp + margin compounding as catalyst; main risk = consumer-discretionary softness in aesthetics.

📊 DIANALITICS RESEARCH INDEXCompany & Thesis Assessment Score /100 — updated 2026-05-30

Evolus, Inc. (EOLS)

Medical Aesthetics · NASDAQ · Newport Beach, CA

"Asymmetric inflection — fallen-angel franchise with proven profitability path, but consumer-cycle and leverage risk are real."

Jeuveau 14% share EBITDA positive 2Q Stockholders' deficit −$29M −42% from 52W high Consumer-discretionary exposure

Fin. strength

/20 pts

EBITDA/FCF

/15 pts

Debt/leverage

/15 pts

Stage/business

/15 pts

Catalysts

/10 pts

Reg. risk

/8 pts

Risk/reward

/7 pts

Management

/5 pts

Sector/macro

/3 pts

Compliance

/2 pts

💡 Fair Value Estimate — Forward EV/Sales with peer-driven re-rating

Fair value base case

USD 8.30

Range: USD 5.70-USD 15.9

Price at analysis date: USD 6.18 (30/05/2026)

Base upside/downside: +34%

Methodology: Forward EV/Sales is the appropriate primary metric for an aesthetic-medicine name at the EBITDA-inflection stage: FCF is still negative, GAAP earnings are uninformative, but revenue trajectory and gross-margin trend (66.9% in Q1) are the value drivers. EV/EBITDA serves only as a sanity check at FY27E. The fair value range $5.70–$15.90 is intentionally wide because it reflects whether the market chooses to price EOLS as an aesthetic-pharma growth name (INMD/HIMS bucket) or as a sub-scale challenger with leverage (APYX bucket). ⚠️ Not investment advice.

Component	Assumption	USD/share
Jeuveau core franchise	2.0x EV/Sales fw × ~$285M Jeuveau revenue FY26E (87% of mix)	+8.66
Evolysse HA filler	2.5x EV/Sales fw × ~$47M revenue FY26E (early ramp premium vs Jeuveau)	+1.79
Option value: international (Symatese)	25% probability × $50M NPV (Asia/EU rollout)	+0.19
Net debt (Q1 26)	$49.8M cash − $156.4M LT debt = −$106.6M / 65.84M sh.	−1.62
Dilution haircut (1Y)	−3% adjustment for ongoing share-based comp (+3.95% YoY trend)	−0.28
Execution risk discount	−5% for Q1 revenue micro-miss + Middle East cost drag flagged by mgmt	−0.44
FV base case	Sum: 8.66 + 1.79 + 0.19 − 1.62 − 0.28 − 0.44 ≈ $8.30	≈ $8.30

Bull

$15.90

Probability: 25%

FY26 prints at top of guide ($337M), Evolysse beats with $55M+, Adj EBITDA hits 5%+ ($17M). Peer-median re-rate to 3.0x EV/Sales on FY27E ~$385M → $15.90/sh. Catalyst: 2-3 quarters of clean execution + strategic M&A interest.

Base

$8.30

Probability: 50%

FY26 guide hit at mid-point ($332M), Adj EBITDA at low end of "low-to-mid SD margin" (~$10M). Re-rate to 2.0x EV/Sales fw. Stock crosses the $8 line on the Q2 print confirming guide.

Bear

$5.70

Probability: 25%

Aesthetic spend weakens, Jeuveau share slips below 14%, FY26 revenue lands at low end ($327M) and EBITDA goes back to break-even. Multiple compresses to 1.4x EV/Sales fw, equity to $5.70 (−8%). 52W low at $3.86 represents the panic floor.

Methodology: Methodology: Forward EV/Sales is the appropriate primary metric for an aesthetic-medicine name at the EBITDA-inflection stage: FCF is still negative, GAAP earnings are uninformative, but revenue trajectory and gross-margin trend (66.9% in Q1) are the value drivers. EV/EBITDA serves only as a sanity check at FY27E. The fair value range $5.70–$15.90 is intentionally wide because it reflects whether the market chooses to price EOLS as an aesthetic-pharma growth name (INMD/HIMS bucket) or as a sub-scale challenger with leverage (APYX bucket). ⚠️ Not investment advice. Not investment advice.

check_circle

✅ EBITDA Inflection Confirmed — Two Consecutive Quarters Positive

Q4 2025 and Q1 2026 both delivered positive Adjusted EBITDA ($0.6M in Q1 26 vs −$5.5M Q1 25) despite Q1 being seasonally the weakest quarter. Management reaffirmed FY26 guide and explicitly framed FY26 as "the first year of profitable growth", a re-rating gate the market has not yet priced in.

⚠️ Methodology note: EOLS is treated as an "asset-light branded specialty aesthetics" profile. Primary FV method: forward EV/Sales with margin-driven re-rating tilt; secondary cross-check: forward EV/EBITDA at FY27E run-rate. Discounted-cash-flow is not anchored here because FCF is still negative in FY26 by management's own guide.

📊 Capital Structure · Short Interest · Buyback & Dilution

🟡 Short Interest

10.43%

6.62M shares short on ~63.5M float. Moderate-to-elevated; partially driven by post-guide cut sentiment in Jan-Feb 2026. Days-to-cover not crisply disclosed; squeeze potential limited but real on a clean Q2 beat.

🟡 Share dilution (1Y)

+3.95%

From ~63.3M to 65.84M shares (Q1 26). Cause: routine SBC vesting + RSU grants. No equity raise in last 12 months. Insider activity dominated by 10b5-1 tax-related sells.

🔴 Buyback

No active buyback program. Priority is deleveraging (Pharmakon term loan up to $250M facility) and funding Evolysse rollout. Buyback unlikely before sustained FCF positive (FY27 at earliest).

Short Interest — context

EOLS — 10.4%

10.4%

Interpretation: ~10% short interest is moderate (sector median is ~6-8% for small-cap healthcare). Reflects skepticism on FY26 guide attainability after January's cut from $20+ targets to $13-17, not structural distress. Insider Form-4 sells in March 2026 (David Moatazedi: 116,720 sh @ $4.89, $571K) were under 10b5-1 plan and tax-driven, not directional. A Q2 beat could trigger meaningful short-cover.

$Financial analysis — FY 2023–2026E

FY26E Revenue

$327–337M

+10% YoY (mid-point)

Q1 26 Adj EBITDA

+$0.6M

vs −$5.5M Q1 25

Cash (Q1 26)

$49.8M

−$11.9M YoY (mid-25)

LT Debt (Q1 26)

$156.4M

+$10.3M vs FY25

Item	FY2023	FY2024	FY2025	FY2026 Guidance
Net revenue ($M)	202.1	266.3	~298	327–337
YoY growth %	+36%	+32%	+12%	+10%
Adj gross margin %	~69%	~70%	~67%	65.5–67%
Non-GAAP opex ($M)	~185	~210	~232	210–216
Adj EBITDA ($M)	~−15	0.3	~5	~10–17 (low-to-mid SD margin)
GAAP net loss ($M)	−83	−65	~−47	~−30

FY25 figures estimated from guide ($295-305M) and Q1-Q3 reports. Adj EBITDA FY26 derived from "low-to-mid SD margin" guide × mid-point revenue. Non-GAAP opex compression in FY26 = first real cost discipline year.

Quarterly dynamics — last 5 quarters
Metric	Q1 25	Q2 25	Q3 25	Q4 25	Q1 26
Revenue ($M)	68.4	73.0	75.5	~81	73.1
Gross margin %	~68%	~70%	~68%	~67%	66.9%
Net loss ($M)	−17.6	−12.5	−10.3	−7.8	−10.7
End-of-period cash ($M)	67.9	61.7	~55	~54	49.8

Financial position and sustainability

Cash runway (months)

~18–24 mo

Jeuveau U.S. market share

14%

Reorder rate

~71%

Account penetration U.S.

>60%

account_tree

Business model — Aesthetic-medicine dual franchise

From single-product challenger to dual-franchise specialty aesthetics

Evolus is a U.S.-based commercial-stage aesthetic medicine company built around Jeuveau (FDA-approved neurotoxin, 2019), with the Evolysse hyaluronic-acid (HA) filler collection commercialized through a partnership with French manufacturer Symatese. The customer base is U.S. licensed aesthetic injectors (~60% account penetration). Distribution model is direct-to-practice with the Evolus Rewards consumer-loyalty platform (~1.5M members, +27% YoY) acting as a brand-pull engine. The strategic thesis: dual-product penetration into existing accounts unlocks operating leverage and meaningfully changes EBITDA margin trajectory without proportional opex.

Jeuveau (neurotoxin) ~$285M FY26E (~87% rev) 🟢 mature, share-stable FDA-approved botulinum toxin for glabellar lines. 14% U.S. market share (Botox/Dysport/Xeomin/Daxxify competing). 71% reorder rate confirms franchise stickiness. GM target 70%+. Evolysse (HA fillers) ~$45–55M FY26E (~14% rev) 🟢 ramping HA filler collection launched 2025 through Symatese. Q1 26: $6.7M, 2nd full quarter. Cross-sell into existing 60% account base. Lower GM than Jeuveau initially but scales fast on volume. International (Nuceiva + EU/Asia) ~$5–10M FY26E (<3% rev) 🟡 optionality Outside U.S.: Nuceiva (Jeuveau brand) in selected markets. Largely unmonetized today. Symatese partnership enables Asia rollout. Pure option value — not in base case.

gavel

Legal, regulatory and risk analysis

Consumer-discretionary aesthetic spend

High

Aesthetic procedures are deferrable. A consumer slowdown, especially in Tier-2/3 U.S. metros, hits volume immediately. Q1 26 +7% growth (vs +15% trailing) is an early warning sign that the cycle is softening.

Stockholders' deficit / leverage

High

Negative book equity (−$28.8M Q1 26) and $156M LT debt vs $49.8M cash. Pharmakon facility provides up to $250M but at term-loan economics. EBITDA must scale or refi terms tighten.

Middle East logistics / packaging cost

Moderate

Management explicitly guided FY26 Adj EBITDA "toward the low end" of $25–35M range citing conflict-driven shipping cost. Risk is incremental, not existential, but materializes through GM compression.

Competitive intensity neurotoxin

Moderate

Daxxify (Revance/Crown), Botox (AbbVie), Dysport (Galderma), Xeomin (Merz) all fight for share. Jeuveau's 14% has been stable for 4+ quarters — the franchise is defended, but pricing power is bounded.

Insider 10b5-1 sells

Moderate

CEO David Moatazedi sold 116,720 sh @ $4.89 (~$571K) on Mar 17, 2026 under 10b5-1 plan. Tax/PSU-vesting context — mechanical, not directional — but cumulative C-suite sales above $500K threshold across multiple insiders. Worth tracking.

Jeuveau franchise floor

Positive

Floor anchor: ~$285M revenue franchise with 70% GM, 71% reorder rate, 60% U.S. account penetration. Even in bear case the franchise generates ~$200M gross profit — the asymmetry rests on this as a real, not nominal, floor.

Legacy litigation resolved

Positive

2020 SDNY securities class action dismissed without prejudice. Medytox + Daewoong IP litigation settled (2021/2023) with Evolus receiving $25.5M from Daewoong. No active material lawsuit as of May 2026.

Evolysse cross-sell optionality

Positive

HA filler line into installed Jeuveau-injector base is the cleanest near-term operating-leverage lever. Each $10M of incremental Evolysse at 50%+ GM with no extra salesforce drops mostly to EBITDA. Q1 26 prints ($6.7M) confirm traction.

article

SWOT analysis

Strengths

+14% stable U.S. neurotoxin market share with 71% reorder rate
+Dual-product franchise (Jeuveau + Evolysse) — operating-leverage unlock
+Two consecutive quarters of positive Adj EBITDA confirm inflection
+~$200M+ revenue gross-profit floor anchors asymmetric thesis
+Consumer brand (Evolus Rewards, 1.5M members) lowers patient-side CAC

Weaknesses

−Stockholders' deficit (−$28.8M) and net debt $107M vs cap $407M
−FCF still negative in FY26 by management's own guide
−Q1 26 revenue +7% YoY — growth slowing materially
−3.95% YoY share dilution from SBC, no buyback offset
−Heavy reliance on U.S. market and Jeuveau (~87% of revenue)

Opportunities

→Evolysse cross-sell into 60%-penetrated Jeuveau accounts
→EBITDA margin scale-up: low-SD → mid-SD → high-SD over FY26-28
→International rollout (Symatese-enabled EU/Asia) as option value
→Strategic M&A target: aesthetic platforms (Galderma/AbbVie) at <3x sales
→Short-cover catalyst on Q2 print confirming FY26 guide

Threats

!Aesthetic-spend cyclical weakness (consumer-discretionary risk)
!Daxxify / Botox pricing pressure compressing Jeuveau ASP
!Pharmakon term-loan terms tightening if EBITDA disappoints
!Middle East logistics cost extending beyond FY26
!Continued insider selling signaling muted management conviction

article

Summary by assessment area

Asymmetry thesis

Floor: ~$285M Jeuveau franchise + 70% GM = real cash-flow anchor
Downside to bear case ($5.70): −8%; to 52W low ($3.86): −38%
Upside to base ($8.30): +34%; to bull ($15.90): +157%
Ratio ~3-4x in expected-value terms — qualifies asymmetry gate

Catalyst path

Q2 2026 earnings (early Aug) — first FY26 guide validation
Evolysse run-rate: $8–10M/qtr by Q3 26 = re-rating gate
Adj EBITDA margin trajectory: low-SD → mid-SD by Q4 26
Short-cover (10.4% SI) on clean execution sequence

Trade-off & verdict

Enter only with size discipline (3–5% position max)
Pair-trade: long EOLS vs short consumer-discretionary aesthetic ETF
Hard stop: Jeuveau share dropping below 12% OR FY26 guide cut
Time horizon: 12–18 months; target $8–10, optionality to $15+

2026-08-05 earnings

Q2 2026 Earnings — first FY26 guide validation

short-term Impact: High Direction: Binary

Critical print for the asymmetry thesis. Revenue ~$80M+ needed to keep FY26 $327-337M guide intact. Evolysse run-rate above $8M signals operating-leverage thesis on track. A miss reopens the door to another guide cut.

2026-08-05 product

Evolysse Q2 run-rate > $8M (cross-sell test)

short-term Impact: High Direction: Bullish

HA filler line is the operating-leverage lever. $6.7M in Q1 → $8M+ in Q2 confirms cross-sell into Jeuveau accounts. Each $10M incremental drops mostly to EBITDA. Failure to ramp would compress the 2.5x EV/Sales multiple applied to Evolysse in base FV.

2026-11-05 earnings

Q3 2026 Earnings + early FY27 framework

medium-term Impact: High Direction: Binary

Window where management typically signals FY27 framework. Mid-SD margin trajectory toward $25-30M EBITDA at $385M revenue would justify re-rate to 2.5x EV/Sales (bull case path). Missing this signal pushes thesis into FY28.

2026-12-31 capital_markets

Pharmakon term-loan refinancing assessment

medium-term Impact: Medium Direction: Neutral

$156M LT debt with up to $250M Pharmakon facility headroom. If EBITDA expansion delivers, refi at lower spread is a quiet positive. If EBITDA disappoints, covenant tightening becomes a real overhang.

2027-02-28 partnership

International rollout commentary on FY25 print

long-term Impact: Medium Direction: Bullish

Asia rollout through Symatese is option value not in base FV. Management commentary on FY25 print could quantify the international ramp, adding $0.50–$1.00/sh to the SotP.

2026-09-30 ma

Aesthetic-medical M&A read-through (Revance precedent)

medium-term Impact: Medium Direction: Bullish

Revance was taken private by Crown Labs at $924M in 2024 (~3x sales). At $407M cap, EOLS sits well below the precedent take-out multiple. Strategic M&A interest from Galderma / AbbVie / private aesthetic platforms is a non-zero tail.

Sources & Disclaimer

Sources: Evolus 10-Q Q1 2026 (SEC EDGAR), Evolus 8-K Q1 2026 (May 4, 2026), Q1 2026 earnings call transcript (Motley Fool), StockTitan EOLS news, ChartMill EOLS analysis, Yahoo Finance EOLS, MarketBeat EOLS forecast, Stifel/BTIG/HC Wainwright/Mizuho analyst notes (Jan-Feb 2026), Form 4 insider trading (March 2026), Vital Law SDNY class-action dismissal note. Market data — last verified close 2026-05-29 ($6.18, Yahoo Finance previous-close cross-checked with Morningstar and Kraken; T-1 trading day from report date 2026-05-30). Cross-check vs May 26 verified close $6.25 and May 27 open $6.05 confirms price band $6.00–$6.30. This document is for informational purposes only and does not constitute financial or investment advice. ⚠️ Not investment advice.